A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of PRX002 Administered by Intravenous Infusion in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 13 Dec 2016
Price : $35 *
At a glance
- Drugs Prasinezumab (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Neotope Biosciences; Prothena
- 13 Dec 2016 Results published in the Prothena Corporation Media Release.
- 13 Dec 2016 According to Prothena Corporation media release, clinical results were published in Movement Disorders Journal.
- 25 Nov 2016 Results published in the Movement Disorders